<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">
placeholder

Loss of MAP3K7 and CHD1 Expression Drive Recurrence, Resistance in Prostate Cancer

minute read

Written by Medscape on April 26, 2021

Loss of MAP3K7 protein expression, seen in approximately 40% of prostate cancer patients, is a major driver of prostate tumor aggressiveness and should be considered for inclusion in management algorithms, researchers say.

Topics: Press Coverage

Comments

Related Stories